摘要
目的:探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的临床疗效及安全性。方法:选取2019年8月至2020年4月安徽医科大学附属安庆医院收治的晚期非小细胞肺癌患者60例,根据随机数字表法分为对照组(29例)和观察组(31例)。对照组患者采用常规化疗方案,观察组患者在对照组的基础上加用卡瑞利珠单抗。比较两组患者的近期疗效、不良反应和远期疗效,干预前后两组患者的细胞免疫功能。结果:观察组患者的总有效率为90.97%(22/31),明显高于对照组的44.83%(13/29),差异有统计学意义(P<0.05)。干预后,两组患者CD4^(+)T淋巴细胞占比、CD4^(+)/CD8^(+)比值较干预前明显升高,且观察组患者明显高于对照组;CD8^(+)T淋巴细胞占比较干预前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。两组患者Ⅰ—Ⅱ级、Ⅲ—Ⅳ级白细胞减少、贫血、皮疹和氨基转移酶升高的发生率比较,Ⅰ—Ⅱ级胃肠道反应、发热的发生率比较,差异均无统计学意义(P>0.05)。截至随访日期,观察组患者的中位生存时间为10.0个月(95%CI=0.894~3.107),对照组患者的中位生存时间为6.0个月(95%CI=0.322~1.119);Log-rank检验结果显示,两组患者Kaplan-Meier曲线的差异有统计学意义(P<0.05)。结论:卡瑞利珠单抗联合化疗可提高晚期非小细胞肺癌患者的近期、远期疗效及细胞免疫功能,且安全可靠。
OBJECTIVE:To probe into the clinical efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer.METHODS:Totally 60 patients with advanced non-small cell lung cancer admitted into Anqing Hospital Affiliated to Anhui Medical University from Aug.2019 to Apr.2020 were selected and divided into control group(n=29)and observation group(n=31)via random number table.The control group was given conventional chemotherapy regimen,while the observation group was given camrelizumab based on the control group.The short-term efficacy,adverse drug reactions and long-term efficacy,cellular immune function before and after intervention were compared between two groups.RESULTS:The total effective rate of observation group was 90.97%(22/31),which was significantly higher than that of the control group(44.83%,13/29),with statistically significant difference(P<0.05).After intervention,the CD4^(+)T lymphocyte proportion and CD4^(+)/CD8^(+)ratio of both groups were significantly higher than before intervention,and those of the observation group were significantly higher than the control group;the CD8^(+)T lymphocyte proportions of both groups were significantly lower than before intervention,and those of the observation group were significantly lower than the control group,with statistically significant differences(P<0.05).There were no statistically significant in differences in the incidence of gradeⅠ-Ⅱand gradeⅢ-Ⅳleukopenia,anemia,rash and elevated transaminases,the incidences of gradeⅠ-Ⅱgastrointestinal reactions and fever between two groups(P>0.05).As of the follow-up date,the median survival time was 10.0 months(95%CI=0.894-3.107)in observation group and 6.0 months(95%CI=0.322-1.119)in control group;the Log-rank test showed that the difference in Kaplan-Meier curve between two groups was statistically significant(P<0.05).CONCLUSIONS:The combination of camrelizumab and chemotherapy can promote the short-term efficacy,long-term efficacy and cellular immune function in patients with advanced non-small cell lung cancer,which is safe and reliable.
作者
刘艳
段爱雄
高艳
李笑秋
LIU Yan;DUAN Aixiong;GAO Yan;LI Xiaoqiu(Dept.of Medical Oncology,Anqing Hospital Affiliated to Anhui Medical University(Anqing Municipal Hospital),Anhui Anqing 246003,China;Dept.of Medical Oncology,the First Affiliated Hospital of Anhui Medical University,Anhui Hefei 230031,China)
出处
《中国医院用药评价与分析》
2021年第10期1169-1172,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
第63批中国博士后科学基金面上资助项目(No.2018M632554)。
关键词
晚期非小细胞肺癌
卡瑞利珠单抗
化疗
细胞免疫
Advanced non-small cell lung cancer
Camrelizumab
Chemotherapy
Cellular immunity
